These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18073170)

  • 21. Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis.
    Brunwasser SM; Snyder BM; Driscoll AJ; Fell DB; Savitz DA; Feikin DR; Skidmore B; Bhat N; Bont LJ; Dupont WD; Wu P; Gebretsadik T; Holt PG; Zar HJ; Ortiz JR; Hartert TV
    Lancet Respir Med; 2020 Aug; 8(8):795-806. PubMed ID: 32763206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Asthma and respiratory syncytial virus. New opportunities for therapeutic intervention].
    Mejías A; Chávez-Bueno S; Ríos AM; Fonseca-Aten M; Gómez AM; Jafri HS; Ramilo O
    An Pediatr (Barc); 2004 Sep; 61(3):252-60. PubMed ID: 15469810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial.
    Scheltema NM; Nibbelke EE; Pouw J; Blanken MO; Rovers MM; Naaktgeboren CA; Mazur NI; Wildenbeest JG; van der Ent CK; Bont LJ
    Lancet Respir Med; 2018 Apr; 6(4):257-264. PubMed ID: 29500030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a protocol for a systematic review.
    Quinn LA; Shields MD; Groves HE
    Syst Rev; 2019 Dec; 8(1):333. PubMed ID: 31856889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence on the Link between Respiratory Syncytial Virus Infection in Early Life and Chronic Obstructive Lung Diseases.
    Baraldi E; Bonadies L; Manzoni P
    Am J Perinatol; 2020 Sep; 37(S 02):S26-S30. PubMed ID: 32772357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
    Escobar GJ; Ragins A; Li SX; Prager L; Masaquel AS; Kipnis P
    Arch Pediatr Adolesc Med; 2010 Oct; 164(10):915-22. PubMed ID: 20921348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term airway morbidity following viral LRTI in early infancy: recurrent wheezing or asthma?
    Stein RT
    Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():29-31. PubMed ID: 19651399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab.
    Faldella G; Alessandroni R; Aquilano G; Vandini S; Lanari M; Silvestri M; Pistorio A; Rossi GA
    J Chemother; 2010 Feb; 22(1):30-5. PubMed ID: 20227990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for a causal relationship between respiratory syncytial virus infection and asthma.
    Wu P; Hartert TV
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):731-45. PubMed ID: 21905783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respiratory syncytial virus: old challenges and new approaches.
    Chávez-Bueno S; Mejías A; Jafri HS; Ramilo O
    Pediatr Ann; 2005 Jan; 34(1):62-8. PubMed ID: 15693217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Factors related to recurrent wheezing after hospitalization with RSV infection with the children who were aged three years old or younger: a questionnaire survey].
    Hosoki K; Nagao M; Hiraguchi Y; Tokuda R; Fujisawa T
    Arerugi; 2009 Nov; 58(11):1513-20. PubMed ID: 20168069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
    Piedimonte G; King KA; Holmgren NL; Bertrand PJ; Rodriguez MM; Hirsch RL
    Pediatr Res; 2000 Mar; 47(3):351-6. PubMed ID: 10709734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective.
    Tulloh RM; Bury S
    Future Cardiol; 2014 Mar; 10(2):235-42. PubMed ID: 24762251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
    Groothuis JR; Nishida H
    Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.